Medical cannabis dropped down the priority list, as we have seen on markets in Europe. It meant that the industry had to constantly rebuild relationships with politicians.
We were always wondering, every time, if the person we met would be for or against medical cannabis.
In December 2024, the situation briefly improved with the nomination of Yannick Neuder as Health Minister. He is known for being a supporter of medical marijuana. The texts under his supervision were submitted to the EU for validation and then sent back. Just a few short months later, a second vote of no confidence led to the downfall of the government.
“At the end of last summer, we considered that the subject was no more than technical; it was in the administrative process to be published,” Péribère says. But with all the chaos we experienced in the autumn, it became political.
Now, with yet another new Minister of Health in place, the question is simply ‘when will (it) be published?’.
Bottleneck on the HAS
Once the framework is published and signed into law, the Haute Autorité de Santé (HAS) must then finalise its crucial reimbursement evaluation, meaning clarity on what patients are expected to pay is also dependent on publication.
In December 2025, HAS explicitly stated it would be unable to complete its work on pricing and reimbursement structures until the Conseil d’État decree governing the evaluation procedure is officially published.
HAS started its evaluation process on July 20, 2025. It set a high-stakes target to deliver final reimbursement suggestions by the Q1 of 2026. The deadline is becoming more and more aggressive, given that the Pilot has been extended beyond March 2020.
HAS is also responsible for determining prescriber training and integration requirements of the broader health system. This means that its decisions have a significant impact on the accessibility to patients and the pace at which the framework will be implemented.
“The challenge is there… In every country, the question is always the education of the prescribers, the quality of the information we will be able to provide them,” Péribère added.
As seen in Europe markets, medical cannabis was pushed down to the bottom of political priorities. It meant that the industry had to constantly rebuild relationships with politicians.
We were always wondering, every time, if the person we met would be for or against medical cannabis.
In December 2024, the situation briefly improved with the nomination of Yannick Neuder as Health Minister. He is known for being a supporter of medical marijuana. The texts under his supervision were submitted to the EU for validation and then sent back. Just a few short months later, a second vote of no confidence led to the downfall of the government.
“At the end of last summer, we considered that the subject was no more than technical; it was in the administrative process to be published,” Péribère says. But with all the chaos we experienced in the fall, the topic became more political.
Now, with yet another new Minister of Health in place, the question is simply ‘when will (it) be published?’.
Bottlenecks in the HAS
Once the framework is published and signed into law, the Haute Autorité de Santé (HAS) must then finalise its crucial reimbursement evaluation, meaning clarity on what patients are expected to pay is also dependent on publication.
In December 2025, HAS explicitly stated it would be unable to complete its work on pricing and reimbursement structures until the Conseil d’État decree governing the evaluation procedure is officially published.
HAS started its evaluation process on July 20, 2025. It set an ambitious goal of making final recommendations for reimbursement by the Q1 of 2026. The deadline is becoming more and more aggressive, given that the Pilot has been extended beyond March 2020.
HAS’ important decisions also include prescribing training and integration of the healthcare system. This will impact patient access and speedy implementation.
“The challenge is there… In every country, the question is always the education of the prescribers, the quality of the information we will be able to provide them,” Péribère added.
Cannabis Law Resources in Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. You can use these resources to learn about the requirements for certifications, permissions and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland